Table 2 All-grade AEs occurring in ≥ 10% of patients and corresponding grades 3 and 4 AEs
| Â | Everolimus 10Â mg/day (n = 64) | ||
|---|---|---|---|
AE, n (%) | All-grade | Grade 3 | Grade 4 |
Anemia | 41 (64) | 10 (16) | 3 (5) |
Hypertriglyceridemia | 35 (55) | 4 (6) | 0 (0) |
Mouth ulceration | 34 (53) | 2 (3) | 0 (0) |
Hyperglycemia | 33 (52) | 8 (13) | 0 (0) |
Hypercholesterolemia | 32 (50) | 0 (0) | 0 (0) |
Pyrexia | 26 (41) | 1 (2) | 0 (0) |
Increased blood lactate dehydrogenase | 24 (38) | 1 (2) | 1 (2) |
Fatigue | 20 (31) | 1 (2) | 0 (0) |
Increased gamma-glutamyltransferase | 20 (31) | 7 (11) | 0 (0) |
Rash | 20 (31) | 0 (0) | 0 (0) |
Increased blood creatinine | 19 (30) | 0 (0) | 1 (2) |
Cough | 18 (28) | 0 (0) | 0 (0) |
Increased aspartate aminotransferase | 17 (27) | 0 (0) | 0 (0) |
Increased alanine aminotransferase | 15 (23) | 1 (2) | 0 (0) |
Epistaxis | 15 (23) | 1 (2) | 0 (0) |
Hypocalcemia | 14 (22) | 0 (0) | 0 (0) |
Interstitial lung disease | 14 (22) | 1 (2) | 0 (0) |
Leukopenia | 14 (22) | 0 (0) | 0 (0) |
Pruritus | 14 (22) | 0 (0) | 0 (0) |
Peripheral edema | 13 (20) | 2 (3) | 0 (0) |
Decreased platelet count | 13 (20) | 1 (2) | 0 (0) |
Diarrhea | 12 (19) | 1 (2) | 0 (0) |
Dyspnea | 12 (19) | 1 (2) | 4 (6) |
Increased blood alkaline phosphatase | 11 (17) | 1 (2) | 0 (0) |
Hypokalemia | 11 (17) | 0 (0) | 3 (5) |
Lymphopenia | 10 (16) | 4 (6) | 0 (0) |
Nasopharyngitis | 9 (14) | 0 (0) | 0 (0) |
Dizziness | 8 (13) | 0 (0) | 0 (0) |
Insomnia | 8 (13) | 0 (0) | 0 (0) |
Increased blood creatine phosphokinase | 7 (11) | 0 (0) | 0 (0) |
Decreased appetite | 7 (11) | 1 (2) | 0 (0) |
Decreased hemoglobin | 7 (11) | 2 (3) | 0 (0) |
Hyponatremia | 7 (11) | 5 (8) | 0 (0) |
Nausea | 7 (11) | 0 (0) | 0 (0) |
Upper respiratory tract infection | 7 (11) | 0 (0) | 0 (0) |
Increased white blood cell count | 7 (11) | 0 (0) | 0 (0) |